Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Bone Biologics (BBLG) EBITDA (2016 - 2017)

Bone Biologics (BBLG) has disclosed EBITDA for 2 consecutive years, with -$1.3 million as the latest value for Q4 2017.

  • On a quarterly basis, EBITDA rose 77.03% to -$1.3 million in Q4 2017 year-over-year; TTM through Dec 2017 was -$2.6 million, a 88.58% increase, with the full-year FY2025 number at -$3.2 million, up 23.33% from a year prior.
  • EBITDA was -$1.3 million for Q4 2017 at Bone Biologics, down from -$1.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $2.0 million in Q2 2017 to a low of -$9.1 million in Q1 2016.